Onfasprodil
Onfasprodil (MIJ-821) is a selective intravenous NMDA receptor NR2B subunit negative allosteric modulator (NAM). Onfasprodil inhibits the activity of NR2B-NMDA receptors. Onfasprodil has a rapid antidepressant effect. Onfasprodil can be used for the research of treatment-resistant depression (TRD).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1892581-29-1
- 分子式: C20H23FN2O3
- 分子量:358.41
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
iGluR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
NR2B |
体外実験
N-Methyl-d-aspartate (NMDA) receptors are widely expressed in the mammalian central nervous system (CNS). Activation of the NMDA receptors depends on the simultaneous binding of two co-agonists: glutamate and either glycine or d-serine. Glutamate binds to the GluN2 subunits, and binding of glycine to the GluN1 subunit results in activation via the opening of the channel pore and subsequently causes the flow of ions through NMDA receptors. Functionally, NMDA receptors mediate excitatory synaptic transmission and plasticity by allowing the flux of calcium ions into neurons. NMDA-dependent synaptic plasticity is essential for many types of learning and memory formation. Dysfunction of NMDA receptors has been implicated in many neurological and psychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, neuropathic pain, stroke, brain trauma, schizophrenia, and depression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 1892581-29-1
-
分子量 358.41
-
分子式 C20H23FN2O3
-
SMILES
O[C@H](C1=CC=C(C=N1)O)CN(C2)C[C@](C3)([H])[C@@]2([H])C[C@H]3OC4=C(C=CC=C4)F
-
別名
MIJ-821
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
純度とドキュメンテーション
参考文献
[1]. Gomez-Mancilla B, et al. MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose). Clin Transl Sci. 2023;16(11):2236-2252. [Content Brief]
[2]. Shelton RC, et al. Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study. J Clin Psychiatry. 2025 Aug 6;86(3):23m15246. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)